22.75

4.68% -1.1066

Spyre Therapeutics Inc (SYRE)

Overview News Price History Financials Discussions Forecast

Spyre Therapeutics Inc stock is traded at $22.75, with a volume of 230.34K. It is down -4.68% in the last 24 hours and down -6.60% over the past month. Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.

Previous Close:

$23.86

Open:

$23.72

24h Volume:

230.34K

Relative Volume:

0.39

Market Cap:

$1.44B

Revenue:

$1.23M

Net Income/Loss:

$-214.90M

P/E Ratio:

-5.5197

EPS:

-4.1222

Net Cash Flow:

$-151.25M

1W Performance:

-1.07%

1M Performance:

-6.60%

6M Performance:

-7.36%

1Y Performance:

-5.24%

1-Day Range:

$22.58

$24.39

1-Week Range:

$21.67

$24.83

52-Week Range:

$20.07

$47.97

Spyre Therapeutics Inc Stock (SYRE) Company Profile

Name

Spyre Therapeutics Inc

Sector

Healthcare (1187)

Industry

Biotechnology (679)

Phone

(617) 651-5940

Address

221 CRESCENT STREET, WALTHAM

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

SYRE's Discussions on Twitter

Compare SYRE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SYRE Spyre Therapeutics Inc	22.75	1.44B	1.23M	-214.90M	-151.25M	-4.1222
VRTX Vertex Pharmaceuticals Inc	474.09	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	716.63	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	652.98	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	275.32	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.92	28.75B	3.30B	-501.07M	1.03B	-2.1146

Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-04-24	Initiated	Wedbush	Outperform
Jul-16-24	Initiated	Evercore ISI	Outperform
May-02-24	Initiated	Robert W. Baird	Outperform
Mar-01-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Dec-20-23	Initiated	BTIG Research	Buy
Dec-11-23	Initiated	Guggenheim	Buy
Dec-11-23	Initiated	Jefferies	Buy
May-04-20	Initiated	Piper Sandler	Overweight
Mar-21-19	Initiated	JP Morgan	Overweight
Sep-04-18	Downgrade	Wells Fargo	Outperform → Market Perform
Apr-24-18	Initiated	Evercore ISI	Outperform
Mar-14-18	Reiterated	Needham	Buy

View All

Spyre Therapeutics Inc Stock (SYRE) Latest News

Feb 06, 2025

China Universal Asset Management Co. Ltd. Makes New Investment in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Feb 06, 2025

Feb 05, 2025

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc.SYRE - cnhinews.com

Feb 05, 2025

A company insider recently sold 6,700 shares of Spyre Therapeutics Inc [SYRE]. Should You also Consider to Sale? - Knox Daily

Feb 05, 2025

Financial Analysis: Spyre Therapeutics Inc (SYRE)’s Ratios Unveil Key Insights - The Dwinnex

Feb 05, 2025

Feb 04, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc.SYRE - PR Newswire

Feb 04, 2025